Scarica l'app Stockscreener
5.37
1.10%
-0.06
Dopo l'orario di chiusura:
5.63
0.26
+4.84%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRVI Giù?
Forum
Previsione
Precedente Chiudi:
$5.43
Aprire:
$5.33
Volume 24 ore:
2.31M
Relative Volume:
1.31
Capitalizzazione di mercato:
$761.70M
Reddito:
$288.95M
Utile/perdita netta:
$-119.03M
Rapporto P/E:
9.4293
EPS:
0.5695
Flusso di cassa netto:
$60.67M
1 W Prestazione:
-5.29%
1M Prestazione:
+11.41%
6M Prestazione:
-23.40%
1 anno Prestazione:
-15.70%
Intervallo 1D:
$5.32
$5.62
Intervallo di 1 settimana:
$5.30
$6.01
Portata 52W:
$4.275
$11.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Nome
Maravai Lifesciences Holdings Inc
Settore
Industria
Telefono
(858) 546-0004
Indirizzo
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Confronta MRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
5.37 | 761.70M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Iniziato | Guggenheim | Neutral |
| 2024-12-05 | Downgrade | Goldman | Neutral → Sell |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-08 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Iniziato | Craig Hallum | Buy |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-08-08 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Downgrade | Goldman | Buy → Neutral |
| 2023-01-05 | Downgrade | UBS | Buy → Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-11-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2020-12-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-15 | Iniziato | Credit Suisse | Outperform |
| 2020-12-15 | Iniziato | Goldman | Buy |
| 2020-12-15 | Iniziato | Jefferies | Buy |
| 2020-12-15 | Iniziato | Robert W. Baird | Outperform |
| 2020-12-15 | Iniziato | Stifel | Buy |
| 2020-12-15 | Iniziato | William Blair | Outperform |
| 2020-12-14 | Iniziato | UBS | Buy |
Mostra tutto
Maravai Lifesciences Holdings Inc Borsa (MRVI) Ultime notizie
Maravai Lifesciences initiated with a Neutral at Guggenheim - Yahoo Finance
MRVI Stock Drops 5% Amidst Biotech Sector Decline - GuruFocus.com
Guggenheim starts Maravai LifeSciences stock with neutral rating - Investing.com
Danaher, Cryoport, Sartorius win Buy at Guggenheim (DHR:NYSE) - Seeking Alpha
Guggenheim starts Maravai LifeSciences stock with neutral rating By Investing.com - Investing.com UK
Guggenheim Initiates Coverage on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Exploring December 2024's Undervalued Small Caps With Insider Action In US - Simply Wall St
Maravai LifeSciences reduces debt by $228 million - Investing.com
Maravai LifeSciences (NASDAQ:MRVI) Shares Down 4.8%Time to Sell? - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Up 3.8%Here's What Happened - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences' SWOT analysis: stock outlook amid mRNA manufacturing expansion - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.71 Million Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences' SWOT analysis: stock faces challenges amid growth potential - Investing.com Nigeria
Quantinno Capital Management LP Buys 289,141 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Fmr LLC - MarketBeat
Point72 Asset Management L.P. Sells 2,492,812 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Cut to Sell at The Goldman Sachs Group - Defense World
MRVIMaravai LifeSciences Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Acquired by Systematic Financial Management LP - MarketBeat
Maravai LifeScience shares downgraded on long-term growth concerns in early stage programs - Investing.com Nigeria
138,422 Shares in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Bought by Readystate Asset Management LP - MarketBeat
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors - GlobeNewswire
4 Analysts Have This To Say About Maravai LifeSciences - Inkl
Is Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Still Trending? - Stocks Register
Maravai LifeSciences (NASDAQ:MRVI) Shares Down 3.5% – Here’s What Happened - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Trading Down 3.5%What's Next? - MarketBeat
(MRVI) Proactive Strategies - Stock Traders Daily
Braidwell LP Reduces Stock Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences Holdings (STU:MAR) Net Income Includin - GuruFocus.com
Maravai LifeSciences Holdings (STU:MAR) Capex-to-Operating-Income : 0.00 (As of Sep. 2024) - GuruFocus.com
Investors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Massachusetts Financial Services Co. MA Sells 948,778 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences: Still Struggling To Find Its Footing (NASDAQ:MRVI) - Seeking Alpha
Maravai LifeSciences Holdings (MEX:MRVI) Payments of Debt : MXN-108 Mil (TTM As of Sep. 2024) - GuruFocus.com
Jennison Associates LLC Has $24.77 Million Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Sold by Principal Financial Group Inc. - MarketBeat
Brokerages Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Target Price at $10.33 - MarketBeat
Wolfe Research Initiates Coverage of Maravai LifeSciences Holdings (MRVI) with Peer Perform Recommendation - MSN
Maravai LifeSciences stock plunges 39% amid lowered revenue forecast - MSN
What Do Analysts Think About Maravai LifeSciences Holdings Inc’s (NASDAQ:MRVI) Future? - Stocks Register
Royce & Associates LP Increases Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (NASDAQ:MRVI) Trading Down 7.5%Here's What Happened - MarketBeat
(MRVI) Trading Report - Stock Traders Daily
Maravai Lifesciences stock hits 52-week low at $4.68 - Investing.com
Steven Cohen's Strategic Acquisition in Maravai LifeSciences - GuruFocus.com
Maravai LifeSciences shares initiated with Peerperform on positive aspects - Investing.com India
Maravai lifesci director John DeFord acquires $100,625 in stock - Investing.com
Insider Buying: Director John Deford Acquires Shares of Maravai LifeSciences Holdings Inc (MRVI) - GuruFocus.com
Maravai Lifesciences Holdings Inc Azioni (MRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maravai Lifesciences Holdings Inc Azioni (MRVI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HULL CARL | See Remarks |
Nov 11 '24 |
Buy |
5.64 |
175,000 |
987,000 |
175,000 |
| GTCR INVESTMENT XI LLC | Director |
May 28 '24 |
Sale |
9.81 |
9,940,974 |
97,570,660 |
20,150,005 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):